Sugi Predict

Sugi Predict / Compounds / SCHEMBL9612258

SCHEMBL9612258

SCHEMBL9612258

CC(C)(C)OC(=O)CN1CCN(CC(=O)OC(C)(C)C)CCN(Cc2ccc(CC(=O)NCCN3C(=O)C=CC3=O)cc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ AKT1 P31749 1/20 0.43
▸ KMT2A Q03164 3/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ POLB P06746 1/20 0.40
▸ CHRM4 P08173 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ FAAH O00519 3/20 0.39
▸ ACHE P22303 3/20 0.39
▸ NPFFR1 Q9GZQ6 1/20 0.38
▸ NPFFR2 Q9Y5X5 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ SUCNR1 Q9BXA5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15766907 0.86 AKT1 (0.44) AKT1KMT2ACYP2D6SMN1; SMN2POLB
SCHEMBL15362895 0.86 AKT1 (0.44) AKT1KMT2ACYP2D6SMN1; SMN2POLB
SCHEMBL9612244 0.84 KMT2A (0.47) KMT2ACYP2D6GAASMN1; SMN2POLB
SCHEMBL17586498 0.82 KMT2A (0.44) KMT2ACYP2D6GAASMN1; SMN2POLB
SCHEMBL9972165 0.82 KMT2A (0.43) KMT2ACYP2D6GAASMN1; SMN2POLB
SCHEMBL16356426 0.79 GAA (0.46) KMT2ACYP2D6GAASMN1; SMN2POLB
SCHEMBL30443787 0.78 ALDH1A1 (0.43) KMT2ASMN1; SMN2ALDH1A1LMNA
SCHEMBL16526510 0.78 KMT2A (0.42) KMT2ACYP2D6GAASMN1; SMN2POLB
SCHEMBL17029296 0.78 KMT2A (0.42) KMT2ACYP2D6GAASMN1; SMN2POLB
SCHEMBL9610817 0.77 ITGB3 (0.46) KMT2ASMN1; SMN2ALDH1A1LMNASUCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651411-B1 METHODS AND COMPOSITIONS FOR IMPROVED F-18 LABELING OF PROTEINS, PEPTIDES AND OTHER MOLECULES IMMUNOMEDICS INC (US) 2020-09-16 — — EP disclosed
US-20170283442-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules IMMUNOMEDICS, INC. 2017-10-05 — — US disclosed
US-20160199524-A1 RADIOSENSITIVITY OF FLUOROPHORES AND USE OF RADIOPROTECTIVE AGENTS FOR DUAL-MODALITY IMAGING IMMUNOMEDICS, INC. 2016-07-14 — — US disclosed
US-20150307524-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules IMMUNOMEDICS, INC. 2015-10-29 — — US disclosed
US-9115172-B2 Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules IMMUNOMEDICS, INC. (US) 2015-08-25 — — US disclosed
US-9028800-B2 Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules IMMUNOMEDICS, INC. (US) 2015-05-12 — — US disclosed
US-20150057432-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules IMMUNOMEDICS, INC. 2015-02-26 — — US disclosed
US-20140377177-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules IMMUNOMEDICS, INC. 2014-12-25 — — US disclosed
US-8889100-B2 Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules IMMUNOMEDICS, INC. (US) 2014-11-18 — — US disclosed
US-8808665-B2 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents IMMUNOMEDICS, INC. (US) 2014-08-19 — — US disclosed
US-20140017168-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules IMMUNOMEDICS, INC. (US) 2014-01-16 — — US disclosed
US-8545809-B2 Methods and compositions for improved 18F labeling of proteins, peptides and other molecules IMMUNOMEDICS, INC. (US) 2013-10-01 — — US disclosed
US-20130211044-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules IMMUNOMEDICS, INC. (US) 2013-08-15 — — US disclosed
US-8496912-B2 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents IMMUNOMEDICS, INC. (US) 2013-07-30 — — US disclosed
US-20130171065-A1 In Vivo Copper-Free Click Chemistry for Delivery of Therapeutic and/or Diagnostic Agents IMMUNOMEDICS, INC. (US) 2013-07-04 — — US disclosed
US-8398956-B2 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents IMMUNOMEDICS, INC. (US) 2013-03-19 — — US disclosed
US-20120282178-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules IMMUNOMEDICS, INC. (US) 2012-11-08 — — US disclosed
US-8202509-B2 Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules IMMUNOMEDICS, INC. (US) 2012-06-19 — — US disclosed
US-20120134920-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules IMMUNOMEDICS, INC. (US) 2012-05-31 — — US disclosed
US-20110110854-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules IMMUNOMEDICS, INC. (US) 2011-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150057432-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules F13B, PAICS, MRPL19 AKT1 4609/4885KMT2A 2972/4885CYP2D6 4709/4885
US-20110110854-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules F13B, F13A1, FCGRT AKT1 4413/4885KMT2A 2153/4885CYP2D6 4796/4885
US-20160199524-A1 RADIOSENSITIVITY OF FLUOROPHORES AND USE OF RADIOPROTECTIVE AGENTS FOR DUAL-MODALITY IMAGING BRS3, BRCA1, MRE11 AKT1 2248/4885KMT2A 3986/4885CYP2D6 3996/4885
US-20120134920-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules F13B, FCGRT, PAICS AKT1 4146/4885KMT2A 2486/4885CYP2D6 4787/4885
US-20120282178-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules F13B, F13A1, FCGRT AKT1 4413/4885KMT2A 2153/4885CYP2D6 4796/4885
US-20130211044-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules F13B, F13A1, FCGRT AKT1 4413/4885KMT2A 2153/4885CYP2D6 4796/4885
US-20140017168-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules F13B, FCGRT, PAICS AKT1 4146/4885KMT2A 2486/4885CYP2D6 4787/4885
US-20150307524-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules F13B, PAICS, MRPL19 AKT1 4609/4885KMT2A 2972/4885CYP2D6 4709/4885
US-20130171065-A1 In Vivo Copper-Free Click Chemistry for Delivery of Therapeutic and/or Diagnostic Agents TIE1, C9, NCLN AKT1 4753/4885KMT2A 3209/4885CYP2D6 1307/4885
US-20140377177-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules F13B, FCGRT, PAICS AKT1 4146/4885KMT2A 2486/4885CYP2D6 4787/4885
US-20170283442-A1 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules F13B, PAICS, MRPL19 AKT1 4609/4885KMT2A 2972/4885CYP2D6 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.